• Calendario de Actividades
  • Sobre el Cáncer
  • Empleos
  • Contáctenos
  • Aviso Legal
  • Oficina del Inspector General de Puerto Rico

Centro Comprensivo de Cáncer de la Universidad de Puerto

  • Facebook
  • LinkedIn
  • YouTube
  • Sobre nosotros
    • Junta de Directores
      • Livestream – Reunión de la Junta de Directores del CCCUPR
  • Centro de Radioterapia
    • Misión / Visión / Valores
    • Nuestros Servicios
    • Nuestra Tecnología
    • Facultad Médica
    • Documentos Requeridos al Paciente
    • Publicaciones
  • Hospital
    • Nuestros Servicios
      • Emergencias Oncológicas
      • Clínicas Multidisciplinarias
        • Listado de Médicos Especialistas
      • Centro de Infusión
      • Laboratorio Clínico y Patológico
      • Centro de Imágenes
      • Habitaciones
    • Información de Precios del Hospital
    • Medidas COVID-19
  • Centro De Investigación Y Desarrollo
    • Investigadores
    • División de Biología del Cáncer
    • División Medicina del Cáncer
      • Puerto Rico NCORP
      • AIDS Malignancy Consortium
      • The ANCHOR Study
    • División de Control de Cáncer y Ciencias Poblacionales
      • CAMPO
    • División De Apoyo a la Educación e Investigación
      • Comités Regulatorios
        • Junta de Revisión Institucional (IRB)
        • Salud y Seguridad Ambiental
      • Oficina de Programas Subvencionados
      • Programas Educativos, Básicos y Traslacionales
        • Cancer Research Experience
        • Cursos en línea
          • Principles of Clinical Research and Design
          • Pharmacology: Drug Development
        • Actividades educativas
          • Research of Cancer Epidemiology
          • Decreasing Health Disparities in Cancer Prevention & Diagnosis
        • Programa de internado estudiantes
      • Series Educativas Profesionales 2022
    • Reconocimiento en publicaciones
  • Programas
    • Biobanco
    • CAPAC Training Program
      • CAPAC Information Packet
      • CAPAC Mentors
      • 2022 CAPAC Summer Student Testimonials
      • 2021 CAPAC Summer Student Testimonials
      • Publications
    • Youth Prevention Program
    • Estudiantes
    • PROMIC
      • PROMIC Services
      • PROMIC Service Request Form
  • Noticias y Recursos
    • Comunicados
    • CCCUPR en los Medios
    • Fotogalería
    • Videos
    • Recursos e información

Pablo E. Vivas-Mejia, Ph.D.

Assistant Professor, Department of Biochemistry
School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, PR &
Investigator, Division of Cancer Biology, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR.

Email: pablo.vivas@upr.edu

Complete list of publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=vivas-mejia

Dr. Vivas is highly trained biochemist and cancer biologist whose research focuses on the mechanisms of cancer growth and proliferation, and specifically how ovarian cancer cells become resistant to chemotherapy. His ultimate goal is to stablish an ovarian cancer research program in Puerto Rico that encompass basic and translational research, community, and education of the new generation of cancer researchers. His research purpose is to design and test novel small-interference RNA (RNAi)-and microRNA-based therapies for advanced and drug-resistant ovarian cancer patients. Over his career he has developed cancer-focused cellular and molecular biology expertise as well as experience with the use of cancer mouse models for therapeutic purposes. During the past nine years at the University of Puerto Rico Medical Sciences Campus and in the Comprehensive Cancer Center in particular, he has successfully led and implemented a laboratory focused on cancer biology and ovarian cancer as reflected by my publication record and the trained students. His laboratory uses several biochemical and molecular approaches, and cutting edge technologies to identify and targeting ovarian cancer promoting signaling molecules. For example, his research group published that the oncogene c-MYC is a plausible target for cisplatin resistant ovarian cancer patients. They also showed that the c-JNK1/c-Jun./micro-RNA-21 pathway is upregulated in cisplatin resistant ovarian cancer cells. More recently, they published that the Mir-21 “passenger” strand contributes to the cisplatin resistance of ovarian cancer cells through the targeting of the RNA Binding Protein with Multiple Splicing (RBPMS).

CAPAC Training Program
CAPAC Mentors
CAPAC 2021 Student Testimonials

CAPAC 2021 Student Testimonials

Solicitud de Autorizacion CEE-SA-2020-1449

© Copyright 2016 - 2020 · Centro Comprensivo de Cancer Universidad de Puerto Rico · All Rights Reserved